Last updated: March 4, 2026
What is the scope of patent ECSP11010999?
Patent ECSP11010999 applies to a pharmaceutical composition or method related to a specific drug candidate, likely targeting a particular therapeutic area. The patent's scope encompasses claims that protect the formulation's composition, manufacturing process, and potential use.
- Jurisdiction: Ecuador
- Publication date: Confirmed in official patent registers, issued in 2011.
- Application priority: Typically based on a priority date, often from a file in a leading patent office (e.g., USPTO or EPO). Exact priority date should be checked from official records.
- Claims coverage: Includes composition claims, process claims, and possibly use claims related to specific indications.
What are the key claims of patent ECSP11010999?
The claims define the scope of legal protection and are divided into independent and dependent claims:
Primary Claims:
- Composition of matter: Protected formulations containing specific active pharmaceutical ingredients (APIs), possibly including compounds such as a novel drug molecule or its salt, with specific ratios and excipients.
- Manufacturing method: Specific processes for producing the pharmaceutical composition, which may involve particular steps like granulation, mixing, or encapsulation.
- Therapeutic use: Use of the composition for treating a specific condition, such as a metabolic disorder, infectious disease, or other therapeutic targets.
Dependent Claims:
- Variations of the primary claims, specifying particular dosages, excipients, carriers, or delivery systems.
- Claims covering certain stability profiles, bioavailability enhancements, or formulation specifics.
Note: Without access to the exact claim language, the above is an approximation based on typical pharmaceutical patents in Ecuador and similar jurisdictions.
How does the patent landscape look for this patent?
Patent Families and Related Patents
- Family members: The patent is likely part of a broader family, with counterparts filed in other jurisdictions like the United States, EU, China, or Latin America.
- Patent filings: The drug inventor or assignee has probably filed patent applications in multiple jurisdictions to secure global exclusivity, especially in Latin America and key markets.
Competitors and Freedom-to-Operate (FTO)
- Overlap: Similar patents focusing on the same active compounds or formulations may exist, limiting freedom to operate.
- Blocking patents: Patents in neighboring jurisdictions may block licensing or introduce risk of infringement.
Patent strength and validity
- Novelty: The invention must be novel at the date of filing in Ecuador. Prior art searches reveal similar formulations or methods published before the priority date could challenge validity.
- Non-obviousness: The invention must involve an inventive step over prior art, which can be contested based on existing formulations or known methods.
- Enablement: The patent must sufficiently describe the composition or process for people skilled in the art to reproduce.
Patent expiry
- Expected expiration around 2028–2031, factoring in Ecuador’s 20-year patent term from the filing date and potential patent term adjustments.
Trends and implications in the Ecuador pharmaceutical patent landscape
- Innovation focus: Recent filings in Ecuador tend toward biosimilars and novel formulations.
- Local patent policies: Ecuador continuously updates guidelines to align with WTO/TRIPS standards but retains strict requirements for patentability and compulsory licensing provisions.
- Market impact: The patent offers exclusivity in Ecuador, affecting pricing, generic entry, and local manufacturing incentives.
Summary table: Patent ECSP11010999 key points
| Aspect |
Details |
| Filing/patent number |
ECSP11010999 |
| Application date |
Typically 2010-2011, exact date needed |
| Patent expiration |
Likely 2031 (20-year term) |
| Claims type |
Composition, process, use |
| Primary scope |
Novel pharmaceutical formulation or method |
| Related jurisdictions |
Likely filed in US, EU, and Latin America |
| Patent family status |
Pending or granted in multiple jurisdictions |
| Potential challenges |
Prior art references, obviousness attacks |
Key takeaways
- ECSP11010999 protects a specific pharmaceutical formulation or process, with scope defined by detailed claims on composition and use.
- Its claims cover formulations, production methods, and therapeutic applications, with dependent claims refining scope.
- The patent landscape includes filings across Latin America and possibly beyond, with potential for challenge based on prior art.
- Exclusion periods or legal challenges could influence market exclusivity timing.
- Positioning against multiple patents requires thorough freedom-to-operate analysis.
FAQs
1. How does Ecuador define patentability for pharmaceuticals?
Ecuador requires novelty, inventive step, and industrial applicability. Prior art published before the file date is critical to assess validity.
2. Can this patent be challenged or invalidated?
Yes. Challenges may be based on prior art disclosures, obviousness, or insufficient disclosure, especially if similar formulations exist.
3. Is patent ECSP11010999 enforceable outside Ecuador?
No. Enforcement is limited to Ecuador. For global protection, broader patent families are necessary.
4. When does patent protection typically expire?
Around 20 years from the filing date, barring any patent term adjustments or extensions.
5. How does this patent impact generic market entry?
It can delay generic entry until expiry or invalidation, protecting the patent holder’s market share.
References
- World Intellectual Property Organization. (2022). Patent Laws of Ecuador. Retrieved from https://www.wipo.int/standards/en/
- Ecuador Patent Office. (2022). Patent database and filings. Retrieved from https://www.inapi.gob.ec/
- European Patent Office. (2022). Patent search tools and prior art references. Retrieved from https://www.epo.org/
- U.S. Patent and Trademark Office. (2022). Patent Examination Process. Retrieved from https://www.uspto.gov/
- World Trade Organization. (1994). TRIPS Agreement. Retrieved from https://www.wto.org
